SynOx Therapeutics Raises Additional Funding in Series B Round; Total to $92M
Summary
SynOx Therapeutics, a Dublin, Ireland- and Oxford, UK-based late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, raised additional funding in Series B round. The company intends to use the funds to support a registrational Phase 3 clinical trial of emactuzumab, a CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour (TGCT). Led by CEO Ray Barlow, SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders. The study, named TANGENT, is a global, multi-centre, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the efficacy and safety of emactuzumab in patients with TGCT. Investigators will also assess several secondary outcomes including functional and quality of life measurements, impact on tumour volume, and duration of response.